ClinicalTrials.gg
Active, not recruitingNCT05205031IVIOUpdated Sep 19, 2024

Intravenous Vs. Intraosseous Vascular Access During Out-of-Hospital

A Phase 4 interventional study of Intraosseous access and Intravenous in Cardiac Arrest, sponsored by Lars Wiuff Andersen. Active, not recruiting at 5 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Lars Wiuff Andersen · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,479
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Heart Arrest with a site in Denmark — 6 open to participants now, 11 under way, none of them phase 3. Heart Arrest · Denmark.

Enrollment
5th of 26
1,479 · median 274
Started
2022
with 1 other
Phase 4
5 of 36
2 open now
Primary completion
2024-05
later than 0 of 10 live
Registered
30th of 36
by date
Lead sponsor
4 of 36
Lars Wiuff Andersen

Among the 36 studies in Heart Arrest with a site in Denmark, this one is the 5th largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2022, is one of 5 in phase 4, reaches primary completion later than 0 of the 10 other live ones, and was the 30th registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

6 of the 36 studies in Heart Arrest with a site in Denmark are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Heart Arrest with a site in Denmark, or all of them as a file.
02

Study summary

The "Intravenous vs. Intraosseous Vascular Access During Out-of-Hospital Cardiac Arrest (IVIO)"-trial is an investigator-initiated, randomized, parallel group, patient and outcome assessor-blinded, superiority trial of intravenous vs. intraosseous vascular access during adult out-of-hospital cardiac arrest. The intraosseous group will be further randomized to humeral vs. tibial access. The trial will be conducted in the Central Denmark Region. The primary outcome will be sustained return of spontaneous circulation, and 762 patients will be included. Key secondary outcomes include survival at 30 days and survival at 30 days with a favorable neurological outcome.

03

Conditions studied

  • Cardiac Arrest

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Out-of-hospital cardiac arrest
  2. Age ≥ 18 years
  3. Indication for intravenous or intraosseous vascular access during cardiac arrest

Exclusion criteria

Exclusion Criteria:

  1. Blunt or penetrating traumatic cardiac arrest
  2. Prior enrollment in the trial
  3. Intravenous or intraosseous vascular access already in place and working when the first trial-participating unit arrives on site
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
1,479 participants (actual)

Study arms

  • Active comparator
    Intravenous

    The intervention will consist of attempts to successfully establish a peripheral intravenous access during the cardiac arrest. The prehospital clinician will be required to attempt the intervention a minimum of two times.

    Device: Intravenous

  • Experimental
    Intraosseous

    The intervention will consist of attempts to successfully establish an intraosseous access during the cardiac arrest. The prehospital clinician will be required to attempt the intervention a minimum of two times.

    Device: Intraosseous access

Interventions

  • DeviceIntraosseous access

    Needle placed in the bone marrow.

  • DeviceIntravenous

    Needle placed in a vein.

06

What researchers measure

Primary outcomes

  1. Sustained return of spontaneous circulation

    Palpable pulses or other signs of circulation without a need for chest compressions lasting at least 20 minutes

    Time frame: Before or after hospital arrival (up to 2 hours after the cardiac arrest)

Secondary outcomes

  1. Survival

    Time frame: 30 days after the cardiac arrest

  2. Favorable neurological outcome

    Neurological outcome will be assessed with the modified Rankin Scale (mRS) which is a scale from 0 to 6 assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes. The scale will will be dichotomized as favorable (mRS 0-3) vs. unfavorable (mRS 4-6).

    Time frame: 30 days after the cardiac arrest

07

Study locations

5 sites
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Six months after the publication of the last results, all de-identified individual patient data will be made available for data sharing.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in May 2024, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2022
First posted
Jan 24, 2022
StartActual
Mar 1, 2022
Primary completionActual
May 5, 2024
CompletionEst.
May 5, 2025
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05205031
Lead sponsor
Lars Wiuff Andersen
Collaborators
Central Denmark Region, University of Aarhus
Responsible party
Lars Wiuff Andersen (Associate Professor, Aarhus University Hospital) — Sponsor-investigator
First posted
Jan 24, 2022
Start date
Mar 1, 2022
Primary completion
May 5, 2024
Completion
May 5, 2025 (estimated)
Last update
Sep 19, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion